ArticleInternational ophthalmology2025
Evaluation of choroidal vascularity index and choroidal thickness in patients with primary Sjögren's syndrome.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate choroidal thickness (CT) and choroidal vascularity index (CVI) in patients with primary Sjögren's syndrome (pSS), and to compare these parameters with healthy controls.
methodsThis study included 35 pSS patients and 37 healthy controls. CVI measurements were performed using enhanced depth imaging optical coherence tomography (EDI-OCT). The peripapillary nasal (PPN) and temporal (PPT) regions, with a width of 1000 µm, were analyzed, along with subfoveal (SF) areas at 500, 1000, and 1500 µm. The EDI-OCT images were transferred to ImageJ software for image binarization and CVI calculation. Subfoveal choroidal thickness (SFCT) was also measured.
resultsThere was no statistical difference in age, gender and BMI distribution between the groups (all p > 0.05). All CVI values at 5 different measurement points (SF 500 µm, SF 1000 µm, SF 1500 µm, PPN and PPT) were significantly lower in the pSS group (p = 0.01, p = 0.07, p = 0.017, p = 0.03 and p = 0.019, respectively). SFCT values were found to be significantly lower in the patient group (326.2 ± 89.4 µm vs 380.6 ± 78.2 µm, p = 0.008). A significant positive correlation was found between SFCT measurements and PPN CVI and PPT CVI values (r = 0.515, p = 0.002; r = 0.493, p = 0.003, respectively).
conclusionWe detected significantly thinned CT and decreased CVI values in patients with pSS, for the first time. As a result of our study, CT and CVI measurements may become parameters that can be used in the follow-up of pSS patients in whom no pathology is detected in routine eye examination and perhaps in the evaluation of treatment response.
Indexed as
Identifiers
41160210What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.